<DOC>
	<DOCNO>NCT00959283</DOCNO>
	<brief_summary>RATIONALE : Studying gene express sample blood patient Down syndrome may help doctor identify biomarkers related cancer . PURPOSE : This research study look blood sample newborns Down syndrome .</brief_summary>
	<brief_title>Study Blood Samples From Newborns With Down Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - To biological understanding natural history transient myeloproliferative disorder ( TMD ) relationship subsequent leukemia facilitate development TMD cell protein bank , repository DNA/RNA megakaryoblasts future biological study . - To investigate biology TMD molecular change associate resolution TMD conversion acute myeloid leukemia within mortality-risk group conduct GATA1 mutational analysis , hematopoiesis clonality study , assessment RAS mutation , genomic instability study use glycophorin A assay . - To determine high-resolution microarray genomic analysis TMD blast ( use Affymetrix SNP Genechip technology ass gene expression , copy number variation , loss heterozygosity ) predict development subsequent leukemia . - To determine relationship minimal residual disease ( monitored peripheral blood flow cytometry GATA1 mutational study ) clinical remission status development subsequent leukemia within mortality-risk group TMD patient . - To evaluate relationship karyotype ( include FISH analysis ) subsequent leukemia TMD patient . - To examine pharmacogenetics vitro drug sensitivity cytarabine ( MTT assay ) blast TMD patient . - To examine relationship functional polymorphism Phase I Phase II drug detoxification gene , DNA repair , DNA synthesis pathway may modify susceptibility leukemia outcome TMD patient . - To determine relationship fibrosis-associated serum factor ( e.g. , platelet-derived growth factor , transform growth factor beta , N-terminal peptide III procollagen , type IV collagen , hyaluronic acid ) event-free survival . OUTLINE : This multicenter study . Patients undergo peripheral blood collection periodically biomarker analysis . Samples analyze GATA1 mutation real-time PCR , polymorphism , cytogenetics , - K-RAS mutation , gene expression , drug sensitivity pattern , minimal residual disease flow cytometry . Patients follow periodically 5 year .</detailed_description>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemoid Reaction</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis transient myeloproliferative disorder ( TMD ) &lt; 90 day age meeting 1 follow criterion : A diagnosis Down syndrome Down syndrome mosaicism AND nonerythroid nonlymphoid blast ( amount ) peripheral blood verify second sample Patients typical physical characteristic Down syndrome allow cytogenetic FISH confirmation diagnosis Trisomy 21positive leukemic blast document biopsy organ ( include &gt; 5 % nonerythroid/nonlymphoid blast document bone marrow aspirate biopsy ) Infants isolated trisomy 21 positivity identify leukemic blast allow Institutional immunophenotype characterization require study enrollment PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>acute myeloid leukemia/transient myeloproliferative disorder</keyword>
</DOC>